The present invention relates to variable domains of camelid heavy-chain antibodies (VHH domains) directed against the human CD3ε component of the T cell receptor and specifically to methods of use of said polypeptides for delivering prophylactic, therapeutic or diagnostic compounds to human T lymphocytes. It further describes a novel one-step method for the identification of phage displayed camel monoclonal antibodies.
